Annovis Bio, Inc.

NYSE:ANVS 주식 보고서

시가총액: US$107.6m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Annovis Bio 관리

관리 기준 확인 2/4

Annovis Bio's CEO는 Maria Maccecchini, May2008 에 임명되었습니다 의 임기는 16.25 년입니다. 총 연간 보상은 $ 2.15M, 31.1% 로 구성됩니다. 31.1% 급여 및 68.9% 보너스(회사 주식 및 옵션 포함). 는 $ 11.45M 가치에 해당하는 회사 주식의 9.83% 직접 소유합니다. 11.45M. 경영진과 이사회의 평균 재임 기간은 각각 1 년과 8.6 년입니다.

주요 정보

Maria Maccecchini

최고 경영자

US$2.1m

총 보상

CEO 급여 비율31.1%
CEO 임기16.3yrs
CEO 소유권8.4%
경영진 평균 재임 기간1.1yrs
이사회 평균 재임 기간8.7yrs

최근 관리 업데이트

Recent updates

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom

Sep 27

Annovis Bio Rallies On Missed ITT Parkinson's Study Endpoints

Jul 08

Annovis: Strong Sell Reiteration Prior To Phase 3 Data In Parkinson's Disease

Jun 30

Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question

May 02

Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects

Feb 12

Annovis And Alzheimer's Disease: The Best-Laid Plans

Jan 30

Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials

Jan 20

Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts

Oct 16

Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Sep 08
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely

Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum

Jun 28

Annovis wins EU nod to expand late-stage trial for Parkinson's candidate

Feb 08

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Jan 28
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug

Jan 25

Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look

Oct 06

We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Sep 15
We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely

Annovis Bio announces publication of three U.S. patents covering lead asset

Sep 13

Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate

Aug 24

Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate

Jul 07

Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

May 14
Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans

We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Feb 10
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation

Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

Feb 23
Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?

We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

Jan 01
We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth

CEO 보상 분석

Maria Maccecchini 의 보수는 Annovis Bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$43m

Mar 31 2024n/an/a

-US$48m

Dec 31 2023US$2mUS$668k

-US$56m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$3mUS$636k

-US$25m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$9mUS$510k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$1mUS$420k

-US$5m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$120kUS$120k

-US$991k

Sep 30 2019n/an/a

-US$958k

Jun 30 2019n/an/a

-US$841k

Mar 31 2019n/an/a

-US$715k

Dec 31 2018US$155kUS$120k

-US$714k

보상 대 시장: Maria 의 총 보상 ($USD 2.15M )은 US 시장( $USD 679.79K ).

보상과 수익: Maria 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Maria Maccecchini (73 yo)

16.3yrs

테뉴어

US$2,145,852

보상

Dr. Maria L. Maccecchini, Ph D., serves as Independent Director of Lantern Pharma Inc. from June 08, 2022. She is the Founder of Annovis Bio, Inc. and has been its Chief Executive Officer and President sin...

리더십 팀

이름위치테뉴어보상소유권
Maria Maccecchini
Founder16.3yrsUS$2.15m8.41%
$ 9.1m
Mark White
Chief Business Officer & Directorless than a yearUS$135.43k0.47%
$ 504.0k
Cheng Fang
Senior Vice President of Research & Development2.7yrs데이터 없음데이터 없음
Eve Damiano
Senior Vice President of Regulatory Operations2.7yrs데이터 없음데이터 없음
Melissa Gaines
Senior Vice President of Clinical Operations1.1yrs데이터 없음데이터 없음
Blake Jensen
Head of Qualityless than a year데이터 없음데이터 없음
Hilda Maibach
Senior Vice President of Statisticsless than a year데이터 없음데이터 없음

1.1yrs

평균 재임 기간

경험이 풍부한 관리: ANVS 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Maria Maccecchini
Founder16.3yrsUS$2.15m8.41%
$ 9.1m
Mark White
Chief Business Officer & Director8.7yrsUS$135.43k0.47%
$ 504.0k
Michael M. Hoffman
Independent Chairman of the Board10.7yrsUS$153.92k12.56%
$ 13.5m
Jeffrey Cummings
Chief Medical Advisor & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Gregory Petsko
Member of Scientific Advisory Board7.7yrs데이터 없음데이터 없음
Reid McCarthy
Independent Director3.4yrsUS$143.92k0.056%
$ 60.2k
Sidney Strickland
Chairman of Scientific Advisory Board7.7yrs데이터 없음데이터 없음
Claudine Bruck
Independent Director9.7yrsUS$135.43k0.050%
$ 54.1k

8.7yrs

평균 재임 기간

71.5yo

평균 연령

경험이 풍부한 이사회: ANVS 의 이사회는 경험(평균 재직 기간 8.6 년)으로 간주됩니다.